Happi Staff06.08.20
Evonik and IMCD have reached an agreement on the distribution of Evonik’s range of sodium and potassium alkoxides in UK, Ireland, Nordics, France, Spain, Portugal and The Netherlands.
From June 1, 2020, IMCD will distribute the materials into industrial and pharmaceutical markets, supporting existing customers and growing the business further. Omega 3 markets are not included in the agreement.
Chris Young, director, regulated synthesis commented, “We are extremely pleased to be working with Evonik, the global leader in sodium and potassium alkoxides. IMCD’s in-depth knowledge of the pharmaceutical and industrial synthesis markets will enable us to serve well the existing customers as well as allowing opportunities to grow the business for this key range of products.”
IMCD will market the full range of sodium and potassium alkoxides offered by Evonik. The alkoxides can be used as both reagents and catalysts in applications and markets including pharma & healthcare, flavors & additives and industrial chemical manufacturing.
From June 1, 2020, IMCD will distribute the materials into industrial and pharmaceutical markets, supporting existing customers and growing the business further. Omega 3 markets are not included in the agreement.
Chris Young, director, regulated synthesis commented, “We are extremely pleased to be working with Evonik, the global leader in sodium and potassium alkoxides. IMCD’s in-depth knowledge of the pharmaceutical and industrial synthesis markets will enable us to serve well the existing customers as well as allowing opportunities to grow the business for this key range of products.”
IMCD will market the full range of sodium and potassium alkoxides offered by Evonik. The alkoxides can be used as both reagents and catalysts in applications and markets including pharma & healthcare, flavors & additives and industrial chemical manufacturing.